Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Thu, 03.11.2022       Formycon AG
DE000A1EWVY8

 Press Release // November 3, 2022 Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies Protein and glycoengineering improve pharmacokinetics and efficacy Half-life of more than 14 days comparable to the bioavailability of an antibody Reduction of vi [ … ]
Technical analysis
To the publication
Thu, 03.11.2022       Formycon AG
DE000A1EWVY8

 Press Release // November 3, 2022 Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies Protein and glycoengineering improve pharmacokinetics and efficacy Half-life of more than 14 days comparable to the bioavailability of an antibody Reduction of vi [ … ]
Technical analysis
To the publication
Fri, 28.10.2022       Formycon AG
DE000A1EWVY8

 Press Release // October 28, 2022  Formycon reports final figures for the first half of 2022 Consolidated reporting for the first time under IFRS (International Financial Reporting Standards) Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20,1 million) as well as EBITDA of Euro -7,6 million (H1/2021 IFRS: Euro -9,7 million) and operati [ … ]
Technical analysis
To the publication
Fri, 28.10.2022       Formycon AG
DE000A1EWVY8

 Press Release // October 28, 2022  Formycon reports final figures for the first half of 2022 Consolidated reporting for the first time under IFRS (International Financial Reporting Standards) Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20,1 million) as well as EBITDA of Euro -7,6 million (H1/2021 IFRS: Euro -9,7 million) and operati [ … ]
Technical analysis
To the publication
Fri, 23.09.2022       Formycon AG
DE000A1EWVY8

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 103,00 auf EUR 130,00. Zusammenfassung: Formycon hat bekannt gegeben, dass das bisher nicht genannte Referenzprodukt für FYB206 das Medik [ … ]
Technical analysis
To the publication
Fri, 23.09.2022       Formycon AG
DE000A1EWVY8

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 103,00 auf EUR 130,00. Zusammenfassung: Formycon hat bekannt gegeben, dass das bisher nicht genannte Referenzprodukt für FYB206 das Medik [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Formycon AG
DE000A1EWVY8

    Press Release // September 19, 2022    Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab) Positioning in the field of immuno-oncology with the biosimilar candidate FYB206 Addressable market size expected to be well above USD 20 billion after patent expi [ … ]
Technical analysis
To the publication
Mon, 19.09.2022       Formycon AG
DE000A1EWVY8

    Press Release // September 19, 2022    Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab) Positioning in the field of immuno-oncology with the biosimilar candidate FYB206 Addressable market size expected to be well above USD 20 billion after patent expi [ … ]
Technical analysis
To the publication
Wed, 07.09.2022       Formycon AG
DE000A1EWVY8

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 103,00. Zusammenfassung: Der Umsatz in H1/22 von €17,6 Mio. (FBe: €16,0 Mio.; H1/21: €20,3 Mio.) und das EBITDA von €- [ … ]
Technical analysis
To the publication
Wed, 07.09.2022       Formycon AG
DE000A1EWVY8

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 103,00. Zusammenfassung: Der Umsatz in H1/22 von €17,6 Mio. (FBe: €16,0 Mio.; H1/21: €20,3 Mio.) und das EBITDA von €- [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.